Skip to content

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01970306
Enrollment
78
Registered
2013-10-28
Start date
2013-10-18
Completion date
2023-02-24
Last updated
2023-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Adenocarcinoma

Keywords

Esophageal Reinforcement, ACell MatriStem, 13-178

Brief summary

The purpose of this study is to see if implanting MatriStem will lower the risk of one of the more common complications after stomach or esophagus surgery.

Interventions

DEVICEMatriStem PSM

All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.

Sponsors

Integra LifeSciences Corporation
CollaboratorINDUSTRY
Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient 18 years of age or older * Pathologically confirmed Gastric, Gastroesophageal Junction (GEJ) or Esophageal, adenocarcinoma at either MSKCC or a participating site (biopsy may be performed at other institutions but slides must be confirmed at MSKCC or a participating site, as is routine care at our institution) * Patient undergoing any resection requiring an anastomosis to the esophagus for curative intent. Including but not limited to esophagectomy or total gastrectomy. * Subject is willing to provide written informed consent * Subject is willing and able to comply with the follow-up regimen

Exclusion criteria

* Pregnant or lactating women * Intraoperative evidence of metastatic or locally-unresectable disease * Patients with known sensitivity or allergy to porcine materials. * Patients undergoing any resection requiring an anastomosis to the esophagus for palliative intent.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Anastomotic Leak.up to 10 daysAnastomotic leak will be assessed by clinical observation and one postoperative contrast study (thin-barium Gastrografin or Omnipaque swallow)

Secondary

MeasureTime frameDescription
Stricture Formation Clinically and by Determination of Dysphagia Score90 days postoperativelyPatients will be evaluated in the outpatient clinic and will be assigned a dysphagia score from 0-4 by the RSA. Patients reporting symptoms consistent with stricture will be evaluated with radiographic contrast swallow study or endoscopy.
Number of Participants Who Developed Anastomotic Stenosis90 days post opIf during the follow up period, patients report any symptoms suggestive of anastomotic stricture, a contrast study (esophagram) or endoscopy will be obtained at that time to evaluate for stricture. These tests will be performed as per standard postoperative assessment by the surgeon.

Countries

United States

Participant flow

Participants by arm

ArmCount
Surgical Intervention
Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM.
78
Total78

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyNot able to be treated9
Overall StudyNot eligible3

Baseline characteristics

CharacteristicSurgical Intervention
Age, Continuous66 years
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
71 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
5 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
Race (NIH/OMB)
White
67 Participants
Region of Enrollment
United States
78 Participants
Sex: Female, Male
Female
17 Participants
Sex: Female, Male
Male
61 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
29 / 78
other
Total, other adverse events
8 / 78
serious
Total, serious adverse events
18 / 78

Outcome results

Primary

Number of Participants With Anastomotic Leak.

Anastomotic leak will be assessed by clinical observation and one postoperative contrast study (thin-barium Gastrografin or Omnipaque swallow)

Time frame: up to 10 days

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Surgical InterventionNumber of Participants With Anastomotic Leak.Participants diagnosed with anastomotic leak10 Participants
Surgical InterventionNumber of Participants With Anastomotic Leak.Participants without anastomotic leak68 Participants
Secondary

Number of Participants Who Developed Anastomotic Stenosis

If during the follow up period, patients report any symptoms suggestive of anastomotic stricture, a contrast study (esophagram) or endoscopy will be obtained at that time to evaluate for stricture. These tests will be performed as per standard postoperative assessment by the surgeon.

Time frame: 90 days post op

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Surgical InterventionNumber of Participants Who Developed Anastomotic StenosisNot evaluable14 Participants
Surgical InterventionNumber of Participants Who Developed Anastomotic StenosisAnastomotic stenosis8 Participants
Surgical InterventionNumber of Participants Who Developed Anastomotic StenosisNo anastomotic stenosis56 Participants
Secondary

Stricture Formation Clinically and by Determination of Dysphagia Score

Patients will be evaluated in the outpatient clinic and will be assigned a dysphagia score from 0-4 by the RSA. Patients reporting symptoms consistent with stricture will be evaluated with radiographic contrast swallow study or endoscopy.

Time frame: 90 days postoperatively

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Surgical InterventionStricture Formation Clinically and by Determination of Dysphagia ScoreNot evaluable14 Participants
Surgical InterventionStricture Formation Clinically and by Determination of Dysphagia ScoreNo reported dysphagia54 Participants
Surgical InterventionStricture Formation Clinically and by Determination of Dysphagia ScoreDysphagia10 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026